In today’s briefing:
- Intel Snags Altman To Close Foundry Day Event
- Alnylam Pharmaceuticals: Progress of the HELIOS-B Study & 4 Other Major Drivers
- Deere & Co: Expansion In Precision Agriculture & 5 Other Factors Driving Growth In 2024! – Major Drivers
- China Healthcare Weekly (Feb.23)- TCM Ushers in a Harvest Period, Biotech Bottom-Line, Kelun-Biotech
- Asian Dividend Gems: Youngone Holdings
- Avantor Inc: Is The Growth in the Aerospace and Defense Market Changing The Game? – Major Drivers
- HubSpot Inc: Are They Successfully Implementing AI In Their Operations? – Major Drivers
- CF Industries: Export Opportunities and Global Market Dynamics – Major Drivers
- Applied Materials Inc (AMAT): Is The Escalation In Services Growth A Major Growth Catalyst In 2024? – Major Drivers
- Martin Marietta Materials: Expected Improvements In Housing Market Conditions Could Help Them Recover In 2024 & Beyond! – Major Drivers
Intel Snags Altman To Close Foundry Day Event
- Despite the high-profile announcement of his attendance, his segment was less than 3 minutes long!
- Intel’s CEO alluded to a partnership with OpenAI and implied there’s more to come yet there’s been no public announcement of any such partnership.
- Microsoft’s commitment to use Intel’s 18A is a vote of confidence in their foundry offering. Let’s see how it plays out.
Alnylam Pharmaceuticals: Progress of the HELIOS-B Study & 4 Other Major Drivers
- Alnylam Pharmaceuticals reported solid progress across all business areas in 2023, delivering robust product growth for its four wholly-owned commercial medicines, and reaching a milestone of over 5,000 patients now on an Alnylam commercial RNAi therapeutic.
- The company recorded $1.24 billion in global net product revenues.
- Alnylam also extended its leadership in RNAi therapeutics, including pioneering delivery of RNAi therapeutics to adipose and muscle tissues.
Deere & Co: Expansion In Precision Agriculture & 5 Other Factors Driving Growth In 2024! – Major Drivers
- Deere & Company’s earnings revealed a company operating well in the midst of an increasingly competitive market landscape, with stable demand across the majority of sectors.
- The firm noted solid execution across the cycle with an 18.5% margin for equipment operations in the first quarter.
- Land sales fell by 4% to $12.658 billion while equipment operations also dropped 8% to $10.486 billion.
China Healthcare Weekly (Feb.23)- TCM Ushers in a Harvest Period, Biotech Bottom-Line, Kelun-Biotech
- Thanks to the continuous support of policies, the TCM industry has ushered in a harvest period. So, TCM remains to be a relatively certain field for investment in China healthcare.
- Biotech companies must meet several conditions in order to have good long-term development, such as sufficient financial support, at least one blockbuster product and high moral standard of the management.
- Reasonable valuation of Sichuan Kelun-Biotech Biopharm (6990 HK) is about RMB15 billion. So, we think it is now overvalued. Meanwhile, restricted shares will be lifted 12 months after the IPO.
Asian Dividend Gems: Youngone Holdings
- Youngone Holdings is an attractive deep value stock. Net cash (including short term investments) was 1.1 trillion won at the end of 3Q 2023 (79% of market cap).
- Youngone Holdings is the holding company of Youngone Group. Youngone Corp is best known for its OEM apparel business for major branded companies such as The North Face and Patagonia.
- We found Youngone Holdings using Smartkarma’s Smart Score Screener system.
Avantor Inc: Is The Growth in the Aerospace and Defense Market Changing The Game? – Major Drivers
- Avantor delivered fourth quarter business results at the high end of their guidance across key financial metrics, including a core organic revenue decline of 4.8%, adjusted EBITDA margin of 17.5% and adjusted EPS of $0.25.
- They demonstrated robust cash flow management and considerable debt reduction, exceeding their guidance range.
- The company experienced industry wide headwinds due to inventory destocking and cautious customer spending.
HubSpot Inc: Are They Successfully Implementing AI In Their Operations? – Major Drivers
- HubSpot, a leading software company, provided a generally positive update on the firm’s financial performance, strategic direction, and plans for future growth.
- On the financial front, the firm reported solid results for Q4 2023.
- Revenue grew by 21% year-on-year in constant currency terms, and by 25% for the full year 2023.
CF Industries: Export Opportunities and Global Market Dynamics – Major Drivers
- CF Industries Holdings Inc., a global leader in nitrogen-based fertilizers, reported a strong performance for the full year and fourth quarter of 2023.
- The company posted an adjusted EBITDA and net cash from operations of approximately $2.8 billion each, and a free cash flow of $1.8 billion.
- This robust outcome was attributed to a balanced nitrogen supply-demand situation and energy spreads favoring the company’s low-cost production in North America..
Applied Materials Inc (AMAT): Is The Escalation In Services Growth A Major Growth Catalyst In 2024? – Major Drivers
- Applied Materials delivered a decent result and the management claims to have made a strong start to the current fiscal year, exceeding its earnings projections.
- Strengths identified include the company’s innovation strategy and position at key industry inflections, such as new-foundry logic and developments in its DRAM market where it has captured over 50% of market share.
- Revenue from its advanced packaging product portfolio is predicted to reach nearly $1.5 billion in 2024.
Martin Marietta Materials: Expected Improvements In Housing Market Conditions Could Help Them Recover In 2024 & Beyond! – Major Drivers
- Martin Marietta, a provider of aggregates and heavy building materials, presented a decent financial performance for the full year and fourth quarter of 2023.
- Positive elements in the report include the company’s record financial performance, reaching a milestone of $2.1 billion in adjusted EBITDA. Additionally, the company noted that it had a successful, safe year without any major incidents.
- This was also underpinned by the strong performance of the company’s aggregates business which drove revenues up by over 10% to $4.3 billion.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
